Washington University School of Medicine
The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumors that have returned or have been resistant to treatment.
Step 1 Eligibility Criteria for Tissue Sequencing Inclusion Criteria: * Any patient between the ages of 12 and 25 years of age (inclusive) who was diagnosed with any of the following: * High-grade glioma (HGG); newly diagnosed patients * Diffuse midline glioma (DMG); newly diagnosed patients * A pediatric CNS (brain or spine) tumor of any histologic subtype, who has now developed recurrent or refractory disease. * All patients enrolled in this trial will receive treatment for pediatric CNS tumors, including systemic agents, investigational agents, or radiation therapy, prior to receiv…
At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
Arctuva estimate
Verify or correct the compensation shown for this listing.